Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
about
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorCombination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.ProfileChaser: searching microarray repositories based on genome-wide patterns of differential expression.Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer.Dietary effects of mead acid on N-methyl-N-nitrosourea-induced mammary cancers in female Sprague-Dawley rats.Early detection biomarkers for ovarian cancer.Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer.Targeted therapy for triple-negative breast cancer: where are we?Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.EMP2 is a novel therapeutic target for endometrial cancer stem cells.Cytokeratin 19 (KRT19) has a Role in the Reprogramming of Cancer Stem Cell-Like Cells to Less Aggressive and More Drug-Sensitive Cells.
P2860
Q24301920-3B44EE66-E899-44D3-9A6B-9B41AF0AC18CQ33778101-6B8BEF2B-F6BE-4261-A80C-11256304AB02Q34135475-969FC0E1-DA89-4DC7-A17B-27184AD9B36DQ35571082-20152C94-7D91-452A-A9A5-FC77139B6F55Q35605854-B9170953-BB0F-48BF-8A4C-BF5699A98D3CQ36502246-6E69A7C1-DDBE-4545-9728-DCC85147C68DQ36520143-5530B594-AE8A-4F81-BCCC-9AAE46D8E835Q37723691-2C36084C-26E7-4201-A273-3B988FE14BB3Q38009760-7B27F2BB-F403-4370-8AB3-B3B2BDCE8F85Q38924096-24842E9B-FDA2-4370-983B-89962F33D4CEQ39372888-E8AD578A-B9DC-4F5C-B528-82082915459BQ39494709-8091D991-4023-4B84-A544-B1EB04E8E60FQ42505007-1DB6BA20-BC04-4BE6-8D3A-B3EF0337DE56Q46644180-0609DE56-CF57-47B9-A9AA-2A1093204258Q55143746-F88B74DC-00F3-4278-A609-E3C93CDF789E
P2860
Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Preferential antitumor effect ...... cells of the basal B subtype.
@ast
Preferential antitumor effect ...... cells of the basal B subtype.
@en
type
label
Preferential antitumor effect ...... cells of the basal B subtype.
@ast
Preferential antitumor effect ...... cells of the basal B subtype.
@en
prefLabel
Preferential antitumor effect ...... cells of the basal B subtype.
@ast
Preferential antitumor effect ...... cells of the basal B subtype.
@en
P2093
P2860
P356
P1433
P1476
Preferential antitumor effect ...... r cells of the basal B subtype
@en
P2093
Hiroshi Sonoo
Junichi Kurebayashi
Mika Watanabe
Takuya Moriya
Yuji Kozuka
P2860
P2888
P356
10.1186/1471-2407-10-568
P407
P577
2010-10-20T00:00:00Z
P5875
P6179
1019672318